MHRA Halts UK Supply From Geno Pharmaceuticals’ Goa Facility: The…

Regulatory Event

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Statement of Non-Compliance with GMP against Geno Pharmaceuticals Private Limited’s manufacturing site at Tivim Industrial Estate, Mapusa, Goa, India, following an unannounced inspection conducted June 15 to 23, 2026, and formalized in a statement dated June 25, 2026 (report Insp GMP 52165/19076958-0001). The inspection covered non-sterile solid oral dosage manufacturing — hard-shell capsules and tablets — including packaging, warehousing, and quality control testing operations; semi-solid dosage forms were explicitly excluded from scope. MHRA identified five critical deficiencies and has prohibited further batches from this site entering the UK market until a follow-up inspection confirms adequate corrective and preventive action. Six statements total in the lifetime of MHRA’s Alpha Release public database is a small enough number that each one carries disproportionate signaling weight for companies benchmarking third-country oral solid dose suppliers against UK requirements.

The trigger itself is notable. This was not a routine, scheduled surveillance inspection — MHRA conducted it unannounced, specifically in response to three Class II recalls of medicinal products already supplied to the UK market, meaning the agency had reason to distrust this site’s output before its inspectors arrived. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, a materially lower bar than the Class I recalls reserved for products presenting a reasonable probability of serious harm — yet three such recalls were still sufficient to trigger an unannounced, full-scope inspection rather than a desk-based review, underscoring how seriously MHRA weighs a recurring recall pattern from a single site. The five critical deficiencies MHRA cites span the breadth of a pharmaceutical quality system: failure by senior management to ensure a comprehensively designed and correctly implemented Pharmaceutical Quality System (PQS); inadequate controls to prevent mix-ups and substitution of materials; failure to assess and minimize contamination and cross-contamination risk; deficiencies in the investigation and management of serious quality defects; and, most relevant to the broader pattern this quarter, the generation and retention of unreliable GMP records, compromising data integrity and assurance of product quality. That last finding is not a standalone documentation lapse; paired with the other four, it describes a quality system that could not reliably demonstrate what it manufactured, how, or under what conditions. Each of these five findings, taken individually, would likely warrant a significant CAPA response; taken together, they describe a site where the pharmaceutical quality system was not functioning as an integrated whole, which is generally a harder and slower gap to close than a single corrective action targeting one deficiency in isolation.

What the Record Documents

No U.S. Food and Drug Administration (FDA) Warning Letter has been identified under Geno Pharmaceuticals’ name, and no FDA facility registration or Abbreviated New Drug Application (ANDA) linkage has been confirmed as of this writing. That absence should be treated as unconfirmed rather than as evidence the site has no US market exposure; companies with any commercial relationship to this facility should verify registration status directly against FDA’s public establishment database rather than assume that the lack of a public Warning Letter means the lack of US exposure. Companies that have historically relied on this site, or any site sharing similar third-country, oral-solid-dose risk characteristics, should treat FDA’s absence from this record as an open question to be closed through direct verification, not as a favorable data point.

The specific finding on unreliable GMP records maps closely to 21 CFR 211.68(b) and 211.194(a)(8) on the FDA side, and to EU GMP Chapter 4 (Documentation) on the international side; both frameworks generally require GMP records to be contemporaneous, attributable, and reliable enough to reconstruct what actually happened during manufacture. Where MHRA’s framing goes further than a typical FDA Form 483 observation, which documents inspectional observations rather than a final agency conclusion, is in explicitly tying the documentation failure to product quality assurance at the PQS level, rather than treating it as an isolated records-handling lapse — a framing that, under FDA’s own data integrity guidance, would similarly be expected to drive a system-level CAPA rather than correction of a single record. That interpretation gap is worth naming explicitly for regulatory affairs teams building internal briefing documents: a 483 remains an inspectional observation subject to company response, while a Statement of Non-Compliance with GMP is MHRA’s formal determination following its own review of the inspection findings, and the two instruments carry different weight in a company’s own risk register.

Technical and Quality Context

Any UK marketing authorization holder or wholesaler currently distributing product manufactured at this Goa site should treat the prohibition of supply as immediate and binding: no further batches may enter the UK market until MHRA confirms adequate corrective and preventive action through re-inspection, and existing UK stock should be reviewed against the three Class II recalls that triggered the inspection in the first place. Wholesalers in particular should confirm this directly with their own regulatory affairs contacts rather than assuming a distributor’s existing stock is automatically exempt from the prohibition, since the statement applies to further batches entering the UK market rather than to a fixed inventory cutoff date.

Because Geno Pharmaceuticals’ Goa site is located in a third country, it does not hold a UK manufacturing authorisation for MHRA to suspend; MHRA’s own statement notes that no GMP certificate was issued for this site and recommends that EU competent authorities consider withdrawing any EU GMP certificate tied to it. That distinction matters for how the action should be understood: this is a prohibition of supply into the UK market rather than a license suspension, and companies evaluating this site’s status elsewhere should check each relevant jurisdiction’s own certificate and registration records rather than assume a single global status applies uniformly across authorities. In practice, this means MHRA’s formal enforcement posture toward this site more closely resembles an FDA Import Alert than a Warning Letter alone: both instruments operate at the border, controlling what enters a market, rather than directly revoking a manufacturing license that was never issued to that site in the first place.

Decision Relevance

Recall-triggered, unannounced inspections that surface systemic PQS and data integrity findings are exactly the scenario XGene Consulting’s Warning Letter and non-compliance remediation practice is built for — helping quality and regulatory teams build a defensible, system-level CAPA rather than a documentation patch, and helping supply chain teams verify a supplier’s actual certificate and registration status across every jurisdiction that matters to their product. That kind of readiness work is proactive by design: it is meant to be done before a recall pattern forces a regulator’s hand, not after. If your supply chain includes third-country oral solid dose manufacturing sites you haven’t re-verified since before this quarter’s recalls, now is the time. Contact XGene Consulting to scope an inspection-readiness and supplier-verification review.